Antimicrobial activity of a quinuclidine-based FtsZ inhibitor and its synergistic potential with β-lactam antibiotics

Journal of Antibiotics

Volumn 68, Issue 4, 2015, Pages 253-258

  Chan, Fung Yi ^a   Sun, Ning ^a   Leung, Yun Chung ^a   Wong, Kwok Yin ^a  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFOXITIN; CEFTAZIDIME; FTSZ PROTEIN; HYDROLASE INHIBITOR; IMIPENEM; METICILLIN; OXACILLIN; QUINUCLIDINE 1; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAM; CYTOSKELETON PROTEIN; FTSZ PROTEIN, BACTERIA; QUINUCLIDINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; DRUG POTENTIATION; DRUG STRUCTURE; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROTUBULE ASSEMBLY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENTEROCOCCUS FAECIUM; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS FAECIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMS; CYTOSKELETAL PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; ENTEROCOCCUS FAECIUM; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; QUINUCLIDINES; VANCOMYCIN-RESISTANT ENTEROCOCCI;

EID: 84928951939     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2014.140     Document Type: Article

References (27)

1. Rasko, D. A., Sperandio, V. Anti-virulence strategies to combat bacteria-mediated disease. Nat. Rev. Drug Discov. 9, 117-128 (2010).
2. Payne, D. J. Microbiology. Desperately seeking new antibiotics. Science 321, 1644-1645 (2008).
3. Fischbach, M. A., Walsh, C. T. Antibiotics for emerging pathogens. Science 325, 1089-1093 (2009).
4. Desbois, A. P., Lang, S., Gemmell, C. G., Coote, P. J. Surface disinfection properties of the combination of an antimicrobial peptide, ranalexin, with an endopeptidase, lysostaphin, against methicillin-resistant Staphylococcus aureus (MRSA). J. Appl. Microbiol. 108, 723-730 (2010).
5. Drawz, S. M., Bonomo, R. A. Three decades of beta-lactamase inhibitors. Clin. Microbiol. Rev. 23, 160-201 (2010).
6. Erickson, H. P. FtsZ, a prokaryotic homolog of tubulin. Cell 80, 367-370 (1995).
7. Bi, E., Lutkenhaus, J. FtsZ ring structure associated with division in Escherichia coli. Nature 354, 161-164 (1991).
8. Oliva, M. A., Cordell, S. C., Lowe, J. Structural insights into FtsZ protofilament formation. Nat. Struct. Mol. Biol. 11, 1243 (2004).
9. Singh, P., Panda, D. FtsZ inhibition: a promising approach for antistaphylococcal therapy. Drug news perspect. 23, 295-304 (2010).
10. Kapoor, S., Panda, D. Targeting FtsZ for antibacterial therapy: a promising avenue. Expert Opin. Ther. Tar. 13, 1037-1051 (2009).
11. Lock, R. L., Harry, E. J. Cell-division inhibitors: New insights for future antibiotics. Nat. Rev. Drug Discov. 7, 324-338 (2008).
12. Awasthi, D., Kumar, K., Ojima, I. Therapeutic potential of FtsZ inhibition: a patent perspective. Expert Opin. Ther. Pat. 21, 657-679 (2011).
13. Schaffner-Barbero, C., Martin-Fontecha, M., Chacon, P., Andreu, J. M. Targeting the assembly of bacterial cell division protein FtsZ with small molecules. ACS Chem. Biol. 7, 269-277 (2012).
14. Chan, F. Y. et al. Identification of a new class of FtsZ inhibitors by structure-based design and in vitro screening. J. Chem. Inf. Model. 53, 2131-2140 (2013).
15. Tan, C. M. et al. Restoring methicillin-resistant Staphylococcus aureus susceptibility to beta-lactam antibiotics. Sci. Transl. Med. 4, 126ra135 (2012).
16. Ruiz-Avila, L. B. et al. Synthetic inhibitors of bacterial cell division targeting the GTPbinding site of FtsZ. ACS Chem. Biol. 8, 2072-2083 (2013).
17. Sun, N. et al. Rational design of berberine-based FtsZ inhibitors with broad-spectrum antibacterial activity. PLoS ONE 9, e97514 (2014).
18. Pinho, M. G., Errington, J. Dispersed mode of Staphylococcus aureus cell wall synthesis in the absence of the division machinery. Mol. Microbiol. 50, 871-881 (2003).
19. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Nineteenth Informational Supplement CLSI document M100-S19 CLSI: Wayne, PA, USA, (2009).
20. Lorian, V. in. Antibiotics in Laboratory Medicine 5th edn. Antimicrobial Combinations (eds Pillai S. K., Moellering R. C. J., Eliopoulos G. M.) 365-440 (Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2005).
21. Odds, F. C. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52, 1 (2003).
22. Beuria, T. K. et al. Glutamate-induced assembly of bacterial cell division protein FtsZ. J. Biol. Chem. 278, 3735-3741 (2003).
23. Beuria, T. K., Santra, M. K., Panda, D. Sanguinarine blocks cytokinesis in bacteria by inhibiting FtsZ assembly and bundling. Biochemistry 44, 16584-16593 (2005).
24. Margolin, W. Themes and variations in prokaryotic cell division. Fems. Microbiol. Rev. 24, 531-548 (2000).
25. Haydon, D. J. et al. An inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science 321, 1673-1675 (2008).
26. Knudson, S. E. et al. A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis. PLoS ONE 9, e93953 (2014).
27. Stokes, N. R. et al. Novel inhibitors of bacterial cytokinesis identified by a cell-based antibiotic screening assay. J. Biol. Chem. 280, 39709-39715 (2005).